TY - JOUR
T1 - Guillain-Barre syndrome and its treatment
AU - Douglas, Michael
AU - Winer, John
PY - 2006/10/1
Y1 - 2006/10/1
N2 - Guillain-Barré syndrome typically presents with an acute ascending areflexic weakness, progressing over 4 weeks or less. The most common form of the disease is an acute inflammatory demyelinating polyneuropathy, but other forms with primarily axonal pathologies are well documented. The association of Guillain-Barré syndrome with a range of antecedent infections, particularly Campylobacter jejuni enteritis, is also established. A range of serological and neurophysiological investigations can assist in making an accurate diagnosis. Background information about the syndrome and the evidence base for such treatments are discussed herein.
AB - Guillain-Barré syndrome typically presents with an acute ascending areflexic weakness, progressing over 4 weeks or less. The most common form of the disease is an acute inflammatory demyelinating polyneuropathy, but other forms with primarily axonal pathologies are well documented. The association of Guillain-Barré syndrome with a range of antecedent infections, particularly Campylobacter jejuni enteritis, is also established. A range of serological and neurophysiological investigations can assist in making an accurate diagnosis. Background information about the syndrome and the evidence base for such treatments are discussed herein.
UR - http://www.scopus.com/inward/record.url?scp=33750624589&partnerID=8YFLogxK
U2 - 10.1586/14737175.6.10.1569
DO - 10.1586/14737175.6.10.1569
M3 - Review article
C2 - 17078795
SN - 1473-7175
VL - 6
SP - 1569
EP - 1574
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 10
ER -